NCT03157635 - Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 14, 2016

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Paroxysmal Hemoglobinuria, Nocturnal

Interventions

DRUG

Crovalimab

Crovalimab will be administered as per schedule described in individual arm.

DRUG

Placebo

Placebo will be administered as per schedule described in Part 1 placebo arm.

Trial Locations (14)

Semmelweis Egyetem, 1. Szamu Belgyogyaszati Klinika, Diabetologia, Budapest

Kaposi Mor Teaching Hospital, Dept of Internal Medicine/Hematology, Kaposvár

Uniklinik RWTH Aachen, Aachen

Institut hematologie Centre Hayem CHU paris Saint-Louis Lariboisiere F Widal Hopital St Louis, Paris

Universitätsklinikum Ulm, Ulm

Policlinico Universitario Agostino Gemelli, Rome

Tohoku University Hospital, Miyagi

Osaka University Hospital, Osaka

NTT Medical Center Tokyo, Tokyo

Tokyo Medical University Hospital, Tokyo

University of Tsukuba Hospital, Tsukuba

Pra International Group B.V, Groningen

Severance Hospital, Yonsei University Health System, Seoul

Seoul National University Hosp, Seoul